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Transfer between hospitals as a predictor
of delay in diagnosis and treatment of
patients with Non-Small Cell Lung Cancer –
a register based cohort-study
Maria Iachina1*, Erik Jakobsen2,3, Anne Kudsk Fallesen2,4 and Anders Green2
Abstract
Background: Lung cancer is the second most frequent cancer diagnosis in Denmark. Although improved during the
last decade, the prognosis of lung cancer is still poor with an overall 5-year survival rate of approximately 12%. Delay in
diagnosis and treatment of lung cancer has been suggested as a potential cause of the poor prognosis and as
consequence, fast track cancer care pathways were implemented describing maximum acceptable time thresholds
from referral to treatment. In Denmark, patients with lung cancer are often transferred between hospitals with
diagnostic facilities to hospitals with treatment facilities during the care pathway. We wanted to investigate whether
this organizational set-up influenced the time that patients wait for the diagnosis and treatment. Therefore, the
objective of this study was to uncover the impact of transfer between hospitals on the delay in the diagnosis and
treatment of Non-Small Cell Lung Cancer (NSCLC).
Methods: We performed a historical prospective cohort study using data from the Danish Lung Cancer Registry (DLCR).
All patients diagnosed with primary NSCLC from January 1st 2008 to December 31st 2012 were included. Patients with
unresolved pathology and incomplete data on the dates of referral, diagnosis and treatment were excluded.
Results: A total of 11 273 patients were included for further analyses. Transfer patients waited longer for treatment after
the diagnosis, (Hazard ratio (HR) 0.81 (0.68–0.96)) and in total time from referral to treatment (HR 0.84 (0.77–0.92)), than
no-transfer patients. Transfer patients had lower odds of being diagnosed (Odds Ratio (OR) 0.82 (0.74–0.94) and treated
(OR 0.66 (0.61–0.72) within the acceptable time thresholds described in the care pathway.
Conclusion: Fast track cancer care pathways were implemented to unify and accelerate the diagnosis and treatment of
cancer. We found that the transfer between hospitals during the care pathway might cause delay from diagnosis to
treatment as well as in the total time from referral to treatment in patients with Non Small-Cell Lung Cancer. The
difference between no-transfer and transfer patients persists after adjusting for known predictors of delay.
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Background
In Denmark approximately 4 500 patients are diagnosed
with lung cancer each year which makes it the second
most frequent cancer form in the country. Although sur-
vival rates have improved during the last decade, the
prognosis of lung cancer is still relatively poor with an
overall 5-year survival of 12% [1].
In the late 1990’s, Denmark had significantly higher mor-
tality on lung cancer compared to otherwise comparable
countries [2–4]. Delay in diagnosis and treatment has been
suggested as a potential explanation for the higher mortality
among Danish lung cancer patients since their stage of dis-
ease seemed to be more advanced at the time of diagnosis
and treatment compared to other countries [4, 5].
On this basis, The Danish National Board of Health has
launched several national initiatives with the overall aim
to improve the diagnostic processes as well as the treat-
ment of lung cancer and through this increase the sur-
vival. Examples of these initiatives are the National Cancer
Plans, clinical guidelines and cancer care pathways.
Among other things, the pathways define the maximum
time interval from referral to end of primary investigation
and treatment.
In Denmark, the primary investigation and treatment of
lung cancer are often performed at more than one hospital
unit and often at geographically different settings. The
surgical treatment of lung cancer is limited to four depart-
ments and the oncological treatment to 10 departments.
The primary investigation on the other hand is carried out
at 18 departments on a national basis. This means that
some patients are transferred between hospitals e.g. be-
tween the diagnostic conclusion at the end of primary in-
vestigation and start of treatment.
The delay between referral and diagnosis and from diag-
nosis to treatment is a well-known and well researched
phenomenon [6–16]. Several studies have shown delays for
both diagnosis and treatment of lung cancer and also inves-
tigated and have found potential predictors for delay from
both referrals to diagnosis and from diagnosis to onset of
treatment. Examples of predicting variables are biological
(age, stage, co-morbidity, type of treatment) [6, 16–19], psy-
chological [7], socio-demographic (residential status, socio-
economic status) [6, 7, 20] and organizational (type of
hospital, diagnosis and treatment at two or more different
hospitals [6, 18, 21].
Danish data from The Danish Lung Cancer Registry
(DLCR) have shown problems fulfilling the time thresh-
olds and some patients experience longer delay than de-
fined as acceptable in the cancer care pathways [1].
Due to the well-established and very comprehensive
collection of data in the Danish national registries, we
have the opportunity to investigate organizational factors
that potentially could affect the delay in addition to the
already known factors related to delay.
The objective of this study is therefore to investigate
the significance of primary investigation and treatment
at two or more hospitals on the delay in Danish patients
with Non-Small Cell Lung Cancer (NSCLC). Transfer
between hospitals as a predictor for delay is not com-
monly described in the literature. In this paper we aim
to estimate the effect of transfer on the delay in diagno-
sis and treatment using the national based registers.
Methods
We performed a retrospective cohort study based on
register data from The Danish Lung Cancer Registry.
Definitions
In this paper, “Transfer” refers to patients that undergo
primary investigation and treatment at two or more differ-
ent hospitals at different geographical locations. Con-
versely “No-Transfer” refers to patients that are diagnosed
and treated at the same hospital at the same geographical
location.
The cancer care pathways, as defined in 2009 by The
Danish National Board of Health, determine the max-
imum time intervals for diagnostic processes and treat-
ment as follows:
 Time from referral (time of diagnosis) to end of
primary investigation = 28 days
 Time from end of primary investigation to first day
of treatment = 14 days
 Time from referral (time of diagnosis) to first day of
treatment = 42 days
Referral is defined as the date where the investigating
department receives the referral.
End of primary investigation is defined as the date of
decision on treatment.
First day of treatment is defined as the date of initi-
ation of surgical, oncological, or radiological treatment,
whichever comes first.
The Danish Lung Cancer Register
Since the establishment in 2000, the Danish Lung Cancer
Registry (DLCR) has accumulated data on all cases of lung
cancer as reported from all of the more than 50 depart-
ments involved in the care of primary lung cancer patients
in Denmark [1, 22]. Data are reported to the database
when the diagnostic evaluation has been completed, and
when a specific treatment has been finished. This registry
information is then supplemented with data on the pa-
tient’s vital status retrieved from the Danish Civil Registra-
tion System, and pathology information related to the
lung cancer case from the Danish Pathology Register.
Since 2005 more than 90% of all Danish lung cancer pa-
tients have been included in the database. At present the
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database contains data describing waiting times, diagnos-
tic procedures, staging, surgical procedures, complica-
tions, oncological treatment and survival on more than 45
000 patients [1]. The data needed in this study to describe
potential delay and predictors of delay, are all contained in
the database.
Study population
Patients diagnosed with primary lung cancer from January
1st 2008 to December 31st 2012 were identified in the
DLCR. Cases with a pathologically confirmed diagnosis of
small cell lung cancer (SCLC) were excluded from the
study. Also patients with incomplete data as regards date
of referral to diagnosing hospital, date of diagnosis, date of
referral to treating hospital and date of first treatment
were excluded.
A total of 21 479 patients were identified in DLCR within
the study period. 2841 of these patients had small cell lung
cancer (SCLC). Another 1471 patients were excluded from
the study due to undecided/unresolved pathology. 1805 pa-
tients did not have data on the primary investigation. In
180 cases data error occurred. Finally, data on the treat-
ment were missing in 4328 cases. The final study popula-
tion of 11 273 patients meets the inclusion criteria.
Baseline characteristics
From the DLCR we obtained data on age at the time of
diagnosis (day of referral to the diagnostic department),
disease stage at the time of diagnosis, type of treatment,
FEV1 (Forced expiratory volume in 1 second) and East-
ern Cooperative Oncology Group (ECOG) performance
status on the time of diagnosis and information about
changing a hospital after the primary investigation. We
included information on comorbidity for each patient up
to 10 years before lung cancer diagnosis in the form of
Charlson’s Comorbidity Index [23], using the Danish Na-
tional Patient Register. Baseline patient characteristics
are shown in Table 1.
Statistical methods
Cox proportional hazard multivariable regression was used
to assess the impact of transfer after the end of primary
Table 1 Baseline characteristics of the study population
No transfer (%) Transfer (%) Total (%) P-value
N 4434 6839 11,273
Agea <68 2068 (46.64) 3275 (47.89) 5343 (47.40) 0.198
> = 68 2366 (53.36) 3564 (52.11) 5930 (52.60)
Sex Male 2299 (51.85) 3548 (51.88) 5847 (51.87) 0.976
Female 2135 (48.15) 3291 (48.12) 5426 (48.13)
Stage 0, I, II, IIIa 1611 (36.33) 3450 (50.48) 5061 (44.89) <0.000
IIIb, IV 2799 (63.13) 3347 (48.94) 6146 (54.52)
Missing 24 (0.54) 42 (0.61) 66 (0.59)
Co-morbidity (CCI) 0 2333 (52.62) 3479 (50.87) 5812 (51.56) 0.156
1 1829 (41.25) 2904 (42.46) 4722 (41.99)
>1 272 (6.13) 456 (6.67) 728 (6.46)
Treatment Curative 1287 (29.03) 3435 (50.08) 4712 (41.80) <0.000
Palliative 3147 (70.97) 3414 (49.92) 6561 (58.20)
ECOG 0 1618 (36.49) 3068 (44.86) 4686 (41.57) <0.000
1 1705 (38.45) 2299 (33.62) 4004 (35.52)
>1 1111 (25.06) 1472 (21.52) 2583 (22.91)
Year 2008 1259 (37.24) 747 (62.76) 2006 (100) <0.000
2009 1408 (33.65) 714 (66.35) 2122 (100)
2010 1452 (37.09) 856 (62.91) 2308 (100)
2011 1504 (40.48) 1023 (59.52) 2527 (100)
2012 1216 (47.36) 1094 (52.64) 2310 (100)
FEV1 N (Mean, sd) 3842 (1.83,0.85) 6363 (1.96, 0.89) 10,205 (1.91,0.87) <0.000
Days from referral to treatment Mean(sd) 35.59 (14.58) 40.19 (15.68) 38.38 (15.42) <0.000
Days from referral to diagnosis Mean (sd) 20.26 (11.59) 22.26 (12.43) 21.47 (12.13) <0.000
Days from diagnosis to treatment Mean (sd) 15.33 (9.70) 17.93 (11.09) 16.91 (10.64) <0.000
a68 is the mean age of the patient population
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investigation on delay in the diagnosis, waiting time from
end of primary investigation to treatment and total time
from referral received to first day of treatment adjusting for
age, sex, stage, type of treatment, Charlson’s Comorbidity
Index (CCI), performance status (ECOG), FEV1, and year
of diagnosis. Although Cox regression may indicate that
the transfer has an impact on the delay in diagnosis, waiting
time or total time this impact may be clinically insignificant.
To find out the impact of transfer, on the accordance with
recommendations, we used a multivariable logistic adjusted
for age, sex, stage, treatment, CCI, ECOG, FEV1 and year
of diagnosis. The following variables thus act as con-
founders in a prediction model: Age, low age as age being
lower than 68 years, which is the mean age for the patient
population and high age as being higher than the mean age
for the patient population; Sex, Comorbidity (Charlson Co-
morbidity Index score, CCI): 0 as CCI score of 0, 1 as CCI
score of 1; and 2 as CCI score >1, and Clinical tumor stage:
0 as clinical stage is equal to 0, I, II or IIIa and 1 as clinical
stage is equal to IIIb or IV; ECOG: 0 as ECOG score of 0, 1
as ECOG score of 1, and 2 as ECOG score >1, and FEV1 as
a continuous variable.
Results
A total number of 11 273 cases with NSCLC and
complete data on both primary investigation and treat-
ment were included in the study within the study period
from 2008 to 2012. As regards the variables age, sex and
co-morbidity there were no substantial differences be-
tween the “No-transfer” and the “Transfer” groups.
In the variable “stage” there is significantly more pa-
tients with disease stage 0-IIIa in the Transfer-group
(50.48%) compared to the No transfer-group (36.33%).
Conversely, there are more patients with disease-stage
IIIb-IV in the No transfer-group (63.13%) compared to
the Transfer-group (48.94%). This also applies for the
variable “treatment” where 50.08% of the patients in the
Transfer-group are treated with curative intent versus
29.03% in the No Transfer-group. Curative intent is de-
fined as surgical resection or radiotherapy (stereotactic
therapy or more than 50 GY). In the variable “year” the
development over time is shown. In 2008 62.76% of the
patients were in the No transfer-group and 37.24% in
the transfer-group. The numbers for 2012 were 52.64
and 47.36%, respectively (Table 1).
Based on unadjusted data, the total time from refer-
ral to first day of treatment for the two groups is il-
lustrated in Fig. 1.
Table 2 shows time to event as a result of the Cox
regression analysis.
Hazard Ratio (HR)
 of 1 reflects that patients in the two groups analysed
are diagnosed and treated within the same time
 below 1 reflects that patients in one group waits
longer than the other (e.g. transfer vs no-transfer)
 above 1 reflects that patients in one group wait for a
shorter time than the other.
Table 3 shows the odds of being diagnosed and treated
in accordance with the maximum time intervals, ad-
justed for relevant variables.
Results of the Cox regression analyses show that the
time period from the end of the primary investigation to
treatment for the patients, who were transferred, are sig-
nificantly longer (HR = 0.81 with CI 95% (0.68; 0.96)) than
the no-transfer patients, and that the total time from re-
ferral to treatment is also longer for these patients (HR =
0.84 with CI 95% (0.77; 0.92)). Results of the logistic re-
gression analyses show that the odds of ending a primary
investigation in 28 days from referral is significantly lower
for the patients who were transferred (OR = 0.82 CI 95%
(0.74; 0.92)), as well as the odds of getting treatment in
14 days after the end of primary investigation (OR = 0.66
CI 95% (0.61; 0.72)), and getting treatment in 42 days from
the referral (OR = 0.63 CI 95% (0.58; 0.69)).
Both analyses show a slight effect of age on all time inter-
vals. This indicates that patients above 68 years’ experience
longer time from the end of the primary investigation to
treatment and longer total time than younger patients.
Gender does not seem to have an effect on the defined time
intervals. Women wait marginally longer than men for
treatment after the end of the primary investigation, but
gender has no effect on the chance of being diagnosed and
treated on time.
Overall patients with a high stage of disease have a
significantly faster course of investigation as well as a
significantly shorter time from referral to treatment
(Table 2). Co-morbidity has an impact on all three
time intervals (Table 2) where patients with high
CCI-scores wait significantly longer for diagnosis and
Fig. 1 Kaplan-Meier estimates for “transfer” and “no-transfer” groups
in total time from referral to first day of treatment (in days)
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treatment than patients with low CCI-scores. Patients
treated with curative intend experience significantly
shorter time between referral and end of primary in-
vestigation compared to patients with palliative treat-
ment (Table 2). On the other hand they wait longer
for treatment after the end of the primary investiga-
tion. The difference between the two groups is some-
what equalized in the total time from referral to
treatment. For all time intervals for performance sta-
tus (ECOG), no difference was detected (Table 2).
FEV1 as well as calendar year has no effect on any of
the stated time intervals.
Results in Table 3 show that patients with a high stage of
disease compared to low stage of disease has a substantially
higher chance of being diagnosed and treated in time. The
same tendency is shown for increasing CCI-score and for
patients treated with curative intend. For performance sta-
tus (ECOG), it seems that high performance status (low
ECOG-score) increases the chance of being diagnosed
within the acceptable timeframe and it seems to reduce the
chance of getting treatment in time. The ECOG-level has
no impact on compliance with the total time interval. Cal-
endar year and diagnosis has no effect on the total length
of diagnostic work-ups. Increasing FEV1 increases the
chance of being diagnosed within the acceptable timeframe.
Calendar year has a positive effect on the chance of getting
treatment on time.
Discussion
In Denmark, National Cancer Plans and Cancer Care
Pathways determine acceptable time thresholds for diag-
nosis and treatment of lung cancer, but even though these
plans where implemented as early as 2007 exceedance of
time thresholds still is a problem nationwide. In this study,
we wanted to investigate the impact on delay when trans-
ferred between hospital units, from referral to diagnosis
and treatment in patients with NSCLC in Denmark.
The results show that transfer after finished primary
investigation causes delay in the time interval from fin-
ished primary investigation to treatment and in the total
Table 2 Results of Cox regression analysis
Time from referral to end
of primary investigation
Time from end of primary
investigation to treatment
Total time from referral
to treatment
HR (CI 95%) HR (CI 95%) HR (CI 95%)
Transfer (yes vs no) 1.00 (0.93;1.08) 0.81 (0.68;0.96)a 0.84 (0.77;0.92)a
Age (high vs low) 0.89 (0.86;0.92)a 0.96 (0.91;1.01) 0.90 (0.87;0.94)a
Sex (males vs females) 1.00 (0.95;1.06) 1.03 (1.01;1.05)a 1.02 (0.99;1.06)
Stage (high vs Low) 1.12 (1.08;1.16)a 1.04 (1.00;1.08) 1.43 (1.30;1.56)a
Treatment (cur vs pal) 1.32 (1.24;1.41)a 0.86 (0.78;0.95)a 1.11 (1.00;1.24)
CCI (increasing) 0.93 (0.92;0.95)a 0.94 (0.91;0.98)a 0.91 (0.88;0.93)a
ECOG (increasing) 1.04 (1.01;1.08) 0.98 (0.96;1.00) 1.01 (0.99;1.04)
FEV1 (increasing) 0.99 (0.95;1.03) 1.03 (0.99;1.06) 1.02 (0.99;1.05)
Year (increasing) 0.97 (0.93;1.02) 1.15 (1.08;1.21) 1.08 (1.02;1.14)
asignificance at 95% level
Table 3 Results of Logistic Regression Analysis
Time from referral to end of
primary investigation ≤ 28 days
Time from end of primary investigation
to first day of treatment ≤ 14 days
Time from referral to first day
of treatment ≤ 42 days
OR (95% CI) OR (95% CI) OR (95% CI)
Transfer (yes vs no) 0.82 (0.74;0.92a) 0.66 (0.61;0.72a) 0.63 (0.58;0.69a)
Age (high vs low) 0.85 (0.76;0.94a) 0.91 (0.83;0.99a) 0.78 (0.71;0.86a)
Sex (males vs female) 0.92 (0.83;1.03) 1.05 (0.96;1.14) 1.02 (0.93;1.12)
Stage (high vs low) 2.08 (1.84;2.37a) 1.17 (1.05;1.30a) 2.02 (1.81;2.25a)
Treatment (cur vs pal) 1.68 (1.47;1.91a) 0.72 (0.65;0.81a) 1.23 (1.10;1.38a)
CCI (increasing) 0.83 (0.77;0.91a) 0.91 (0.85;0.97a) 0.84 (0.78;0.90a)
ECOG (increasing) 1.08 (1.03;1.14a) 0.94 (0.90;0.98a) 1.00 (0.96;1.05)
FEV1 (increasing) 0.94 (0.88;1.00) 1.09 (1.04;1.15a) 1.03 (0.98;1.09)
Year (increasing) 0.98 (0.94;1.01) 1.29 (1.26;1.33a) 1.17 (1.05;1.20a)
asignificance at 95% level
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time from referral to treatment, but does not affect the
time from referral to the end of primary investigation.
Furthermore, data shows that the odds of being diag-
nosed and treated within the maximum time intervals
are negatively affected by transfer.
Transfer as a predictor for delay is not commonly de-
scribed in the literature; only a few papers deal with how
organizational factors influences delay. Schultz EM et al.
examine the effect that institutional structures and pro-
cesses of care have on delay, but the results are un-
equivocal [24]. Another study showed that the higher
the number of hospitals visited before confirmed diagno-
sis the longer the delay [25]. In a comprehensive study
of trends and predictors for delay in cancer surgery, ap-
proximately 55,000 patients with lung cancer were in-
cluded. The study showed that patients diagnosed and
treated at different hospitals had a 70% higher risk of ex-
ceeding the limit of time to treatment within 30 days of
diagnosis compared to patients diagnosed and treated at
the same hospital. Literature, however, tends to disagree
on the conclusions on the impact of transfer [17, 26].
There does not seem to be a clear explanation of why
transfer should cause delay. In fact, the very explicit and
detailed description of the components and steps in the
Danish cancer care pathways should prevent any excess
delay and also avoid variation in the delay between hos-
pitals on a national basis. The immediate and intuitive
explanation would be that transfer between hospitals re-
sults in additional communication and administrative
procedures that could slow down the patient pathway.
Therefore great effort has been conducted to eliminate
the possible negative effect of transfer conditional to ad-
ministrative procedures. Thus all departments regardless
of geographical distances have now been allocated to
multidisciplinary teams (MDT) and all patients are dis-
cussed through video link on the MDT conferences with
representatives from all relevant specialties present.
These changes have been implemented during recent
years and the effect still has to be evaluated.
Regarding the other examined variables related to per-
sonal and clinical circumstances of the individual patient,
the results seem plausible from both clinical experience
and the available literature.
Advanced age, high co-morbidity and low performance
status seem to be associated with delay from referral to
diagnosis and in some cases also from diagnosis to treat-
ment and total time [6, 16, 26–29].
The two groups in our study differ in two important
aspects. The No Transfer-group had a higher proportion
of patients in high stage and accordingly a lower treat-
ment rate. This reflects the organizational structure of
the Danish health care system dealing with lung cancer,
where a relatively high number of departments perform
investigational procedures to diagnose lung cancer and a
minor number of departments perform treatment. The
patient pathway in patients with high stage and low per-
formance is therefore terminated before referral in de-
partments without treatment possibilities while, on the
other hand, patients with low stage and high perform-
ance are referred to departments with treatment oppor-
tunities and these departments will thus accumulate low
stage patients.
Patients diagnosed with a low stage tumour wait lon-
ger from referral to treatment than patients with a high
stage tumour. This is a well-known observation related
to the more complex and extensive diagnostic proce-
dures these patients have to go through to define the
treatment adapted to their condition. A low stage of dis-
ease at diagnosis can lead to delay in time to treatment
as it often requires additional investigations to determine
the patient’s suitability for treatment [6, 17–19, 30, 31].
Ellis and Olsson both found that complex diagnostic
procedures cause delay with many different specialists
and many steps from diagnosis to treatment causing
delay [10, 21].
Whether delay in diagnosis and treatment influences
the prognosis and mortality is debated in the literature.
Several studies examine the effect of delay in the diagno-
sis and/or treatment on prognosis but an unequivocal
association has not been demonstrated. On the contrary,
the results seem to be both mixed and even paradoxical
[1, 9, 10, 13, 26, 32–37].
Even if, at present, there is insufficient and inconclu-
sive results concerning the association between delay
and the prognosis of lung cancer, it still seems relevant
to address the excess waiting time for diagnosis and
treatment. It cannot be dismissed that delay affects the
prognosis and delay for diagnosis and treatment can in
any case be psychologically stressful for both patients
and relatives [38–40]. Our study shows a significant dif-
ference between the groups and even though this is of
minor quantitative magnitude, in this light it still might
be of clinically significant importance and the results
should warrant further focus on the limitation of the ef-
fects of transfer between hospitals.
In a recent study, Torring et al. highlighted the com-
plex nature of the waiting time paradox, where the dif-
ference in the prognosis of patients works as a
confounding factor when studying the waiting times,
since priority in the diagnosis and treatment is given to
patients who appear to be more ill. This confounding by
indication could affect our results and explain some of
our results concerning the differences between stages
[41]. In our study we have found that the likelihood of
increased time for diagnostic evaluation and time to
treatment is increased even after stratification for low
versus high stage (data not shown), suggesting that the
confounding effect of stage per se is limited.
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Despite this study being the largest in Denmark address-
ing the subject, the study has some limitations. It is a
register based retrospective study and consequently issues
concerning data completeness, accuracy of dates and algo-
rithms is of importance [1], and furthermore a substantial
number of cases are missing. Of the 17 167 patients with
NSCLC who were potential for inclusion in the study,
6133 patients (36%) were excluded because of missing
data on either the primary investigation or the treatment.
Most likely the lacking data is due to failure to report. The
question is whether there is a systematic underreporting
and how that might influence the results. It is, however,
our conclusion that the number of included patients and
our assumption of an equal distribution of the Transfer
and No transfer patients between the reported and miss-
ing cases, makes the results valid and useful.
Conclusion
We conclude that transfers between hospital units in the
patient course from referral to treatment might cause sig-
nificant delay. The difference between no-transfer and
transfer patients persists after adjusting for known predic-
tors of delay. It remains to be investigated whether this
prolonged time period has any impact on prognosis or
mortality. Despite these limitations our study indicates
that transfer between hospitals might have a significant
impact on the delay, and this should be taken into account
when planning the patient pathway. Caretakers should
consider a primary transfer of patients initially thought to
be suitable for treatment with curative intent and this
policy should be included and defined in guidelines and
definitions of patient pathways.
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